Catalyst raises $40 million for Alterase therapies
This article was originally published in Scrip
Executive Summary
Catalyst Biosciences has raised $40.4 million to fund its Alterase engineered protease therapeutics, including its lead candidate, CB 813, for acute bleeding in haemophiliacs. The US company said that the series C round would fund its operations for several years and advance CB 813 through Phase I/II proof-of-concept studies. CB 813 is an improved factor VIIa that the firm believes will require less dosing to control acute bleeding episodes than other formulations. Catalyst expects to file an IND for clinical testing in early 2009. The investment was led by Essex Woodlands Health Venture, which will appoint Jeff Himawan as its representative on Catalyst's board of directors. Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures also participated in the round.
You may also be interested in...
AB Science lists on Euronext after reducing offer size
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.
Amgen posts strong first-quarter sales but healthcare reform set to bite
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.
Tracleer drives growth for Actelion
Actelion's total revenues leapt up by 24% to CHF502 million ($467 million) during the first quarter due to stronger demand for its pharmaceuticals. The firm's net income rose by 30% to CHF133 million, while its diluted EPS increased from CHF0.83 in the first quarter last year to CHF1.09.